LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep ...
The aura6000 is an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe ... Comparing median values from baseline to six months with therapy (assessed at ...
As an example, we reached a major milestone in our international expansion with the approval of Nexalin's Gen-2 15 mA neurostimulation device by the Brazilian Health Regulatory Agency (ANVISA) on June ...
Deep Brain Stimulation (DBS) involves implanting electrodes in specific areas of the brain that deliver electrical pulses to help regulate abnormal brain activity. This can alleviate symptoms such as ...
Nexalin's next-generation devices, including the Gen-2 15 milliamp neurostimulation device, have been approved in various international markets such as China, Brazil, and Oman. The company's ...